Welcome to our dedicated page for Onconetix news (Ticker: ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on men’s health and oncology, and its news flow reflects that dual emphasis. Company press releases and SEC reports describe a portfolio that includes Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under IVDR, and ENTADFI, an FDA-approved, once-daily pill for the treatment of benign prostatic hyperplasia (BPH). News items often highlight clinical data, regulatory context, and commercialization steps for these assets.
Investors following ONCO news can expect updates on oncology diagnostics, particularly prostate cancer detection, and on men’s health therapeutics. For example, the company has reported new clinical validation data for Proclarix presented at the European Association of Urology congress, detailing performance in large patient cohorts and its potential to reduce unnecessary biopsies. Such news provides insight into how Onconetix positions Proclarix within established diagnostic pathways that rely on PSA testing and risk calculators.
Onconetix news also covers strategic transactions and partnerships. The company has announced the acquisition of Proteomedix, licensing agreements between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and, more recently, a non‑binding letter of intent and a definitive merger agreement with Ocuvex Therapeutics, Inc., followed by a joint announcement of the merger’s mutual termination. These items illustrate how the company evaluates business combinations and licensing to expand or refine its focus.
Another recurring theme in ONCO news is capital markets and listing compliance. Press releases discuss PIPE financings involving Series D and Series E preferred stock and warrants, an equity line of credit with Keystone Capital Partners, and a 1‑for‑85 reverse stock split implemented to address Nasdaq minimum bid price requirements. Updates on Nasdaq notices, hearings, and subsequent positive decisions by a Nasdaq Hearings Panel provide context for the company’s efforts to maintain its listing on The Nasdaq Capital Market.
By monitoring the ONCO news feed on this page, readers can track developments in Proclarix clinical evidence, ENTADFI commercialization, licensing arrangements in oncology diagnostics, and the company’s financing and corporate actions as disclosed in press releases and related SEC filings.
Onconetix (NASDAQ:ONCO) and privately-held Ocuvex Therapeutics have signed a definitive merger agreement in a significant stock-based transaction. Under the terms, Ocuvex shareholders will receive 90% ownership of the combined company, while Onconetix shareholders will retain 10% of the equity interests.
The merger will combine Ocuvex's pipeline of commercial and late clinical stage ophthalmic assets with Onconetix's public market presence. The combined company's board will consist of seven directors, with Ocuvex designating five and Onconetix appointing two. The transaction is expected to close in Q4 2025, subject to regulatory and stockholder approvals.
Onconetix (NASDAQ: ONCO) has received multiple delisting notices from Nasdaq due to several compliance issues. The company faces delisting threats due to: (1) failure to file its Q1 2025 10-Q report, (2) failure to file its 2024 annual 10-K report, and (3) non-compliance with the minimum bid price requirement of $1.00, with shares trading below $0.10 for ten consecutive days.
The company has requested a hearing before the Nasdaq Hearings Panel scheduled for May 27, 2025, which has temporarily stayed the trading suspension. Onconetix has also submitted a stay request on May 1, 2025. The company intends to file both missing reports to regain compliance, though there's no assurance the Panel will grant extensions.
Onconetix (Nasdaq: ONCO) has received a Staff delisting letter from Nasdaq on April 24, 2025, due to failing to file its Annual Report (Form 10-K) for the fiscal year ended December 30, 2024. This violation follows a previous delisting notice from April 18, 2025, regarding non-compliance with the minimum bid price requirement of $1.00 per share.
The company has until May 1, 2025, to request a suspension stay, though approval isn't guaranteed. Onconetix, a commercial-stage biotechnology firm, specializes in men's health and oncology solutions. Their key products include:
- Proclarix® - An EU-approved in vitro diagnostic test for prostate cancer
- ENTADFI - An FDA-approved daily treatment combining finasteride and tadalafil for benign prostatic hyperplasia (BPH)
Onconetix (NASDAQ: ONCO) has signed a non-binding Letter of Intent for a potential business combination with Ocuvex Therapeutics, a private biopharmaceutical company specializing in ophthalmic therapeutics. The proposed transaction would result in Ocuvex shareholders owning approximately 90% of Onconetix's equity interests.
Ocuvex brings an FDA-approved product, Omlonti®, for ocular hypertension and open-angle glaucoma, along with late-stage clinical assets. Onconetix currently owns Proclarix®, an in vitro diagnostic test for prostate cancer approved in the EU, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia.
The transaction completion is subject to due diligence, definitive agreement execution, adequate financing, and regulatory and stockholder approvals. There is no guarantee the transaction will be completed as proposed.
Onconetix (NASDAQ: ONCO) has announced successful clinical validation results for its prostate cancer test Proclarix® in a Danish cohort, presented at the 2025 European Association of Urology congress. The study, involving 808 patients with suspected prostate cancer, demonstrated Proclarix's superior performance compared to traditional diagnostic methods.
In a subgroup of 371 patients with enlarged prostates, Proclarix® showed significantly better results than existing tools, with only 5% probability of missing clinically significant cancer, compared to 14% for %fPSA and 20% for the ERSPC risk calculator. The test reduced unnecessary biopsies by 22% while missing only 3 out of 101 significant cancers.
In the broader study group of 654 patients with PSA levels of 2-20 ng/ml, Proclarix® achieved 96% sensitivity and significantly higher specificity compared to current diagnostic tools.
Onconetix (NASDAQ: ONCO) has announced that new clinical data for its prostate cancer test Proclarix will be presented at the 2025 European Association of Urology (EAU) congress in Madrid, Spain, from March 21-24, 2025.
The presentation, titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort,' will showcase results from a study involving over 800 patients from Lillebaelt Hospital - University Hospital of Southern Denmark.
According to Ralph Schiess, PhD, CEO of Proteomedix (a wholly-owned subsidiary of Onconetix), Proclarix has demonstrated in multiple studies its ability to reduce performed biopsies by ruling out patients with clinically insignificant or no prostate cancer, while maintaining minimal risk of missing clinically significant cases compared to standard care.
Onconetix (NASDAQ: ONCO) received a notice from Nasdaq on December 6, 2024, regarding its failure to file the Q3 2024 Form 10-Q, which violated Nasdaq's continued listing requirements. The company subsequently filed the required report on December 10, 2024.
Onconetix is a commercial-stage biotechnology company specializing in men's health and oncology. The company owns Proclarix®, an EU-approved in vitro diagnostic test for prostate cancer acquired through Proteomedix, and ENTADFI, an FDA-approved daily medication combining finasteride and tadalafil for benign prostatic hyperplasia (BPH) treatment.
Onconetix, Inc. (Nasdaq: ONCO) has announced a $2.0 million private placement of Series C Convertible Preferred Stock and Warrants, along with establishing a $25 million equity line of credit. The private placement includes 3,499 shares of Series C Preferred Stock and warrants to acquire up to 591,856 additional common shares. The Series C Preferred Stock is initially convertible into 776,590 common shares. Warrants have an exercise price of $4.38 per share, exercisable after six months and expiring three years later.
The company will seek stockholder approval for the issuance of shares related to this transaction. Proceeds will be used for working capital and general corporate purposes. Tungsten Advisors served as financial advisor. The equity line of credit allows Onconetix to sell up to $25 million of newly issued common stock to an institutional investor, subject to certain conditions.